Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation
Journal of Veterinary Internal Medicine · 01.11.2025 · 39 (6)
DOI: 10.1111/jvim.70256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 01.11.2025. Verfasst von Kristen Thane und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cummings School of Veterinary Medicine, Tufts University, Grafton, Massachusetts, USA. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Horse Diseases, Hyperinsulinism, Insulin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim Animal Health.
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are promising treatments to manage hyperinsulinemia in horses with insulin dysregulation (ID). Hypothesis The SGLT2i velagliflozin decreases insulin concentration in horses with ID. Animals Privately-owned adult horses (n = 37) with laboratory-confirmed ID (low-dose oral sugar test insulin concentration > 75 μIU/mL).
Methods
Double-blind randomized placebo-controlled trial. Horses received placebo (n = 19) or velagliflozin 0.3 mg/kg PO q24h (n = 18) for 20 weeks (Study Period 1, SP1) immediately followed by a 20-week open-label trial where all animals received velagliflozin (SP2). Analysis of resting insulin, glucose, and triglyceride concentrations and body condition score (BCS) was performed between treatment groups and study periods using a Mann–Whitney U test. For SP1, analysis of changes in biochemical analytes over time was performed using generalized linear mixed effects models (GLMM). Data are reported as median (interquartile range).
Results
In SP1, GLMM indicated a significant effect of treatment on insulin concentration (71 [33–131] μIU/mL in horses receiving velagliflozin and 157 [82–298] μIU/mL in horses receiving placebo; p < 0.0001). The average (95% confidence interval [CI]) effect of velagliflozin treatment on insulin concentration was 155 (90–219) μIU/mL. Horses receiving placebo in SP1 had lower insulin (50 [26–99] μIU/mL) during SP2 (p < 0.0001). All horses experienced a transient increase in serum triglyceride concentration during velagliflozin treatment with no clinical abnormalities reported. In SP1, larger decreases in BCS occurred in horses receiving velagliflozin (median BCS 1 point lower than baseline; p = 0.02) than those receiving placebo.
Conclusions
Velagliflozin significantly decreased resting insulin concentrations in horses with ID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cummings School of Veterinary Medicine, Tufts University, Grafton, Massachusetts, USA.
- Boehringer Ingelheim Animal Health USA, Duluth, Georgia, USA.
- Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
- College of Veterinary Medicine, Mississippi State University, Starkville, Mississippi, USA.
ORCID-Profile: Kristen Thane, Rebecca Klee, Tobias Warnken, Nicholas Frank
Förderung
- Boehringer Ingelheim Animal Health
Zitieren
APA
Thane, K., Voth, R., Klee, R., Warnken, T., Chukwu, V., & Frank, N. (2025). Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation. Journal of Veterinary Internal Medicine, 39(6). https://doi.org/10.1111/jvim.70256
Vancouver
Thane K, Voth R, Klee R, Warnken T, Chukwu V, Frank N. Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation. Journal of Veterinary Internal Medicine. 2025;39(6). doi:10.1111/jvim.70256
BibTeX
@article{Thane2025,
author = {Thane, Kristen and Voth, Rebecca and Klee, Rebecca and Warnken, Tobias and Chukwu, Victor and Frank, Nicholas},
title = {Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
volume = {39},
number = {6},
doi = {10.1111/jvim.70256}
}
EUVIMED